west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "WEN Wu" 2 results
  • Influence of CYP2C9 *3, VKORC1-1639 G>A and CYP4F2 rs2108622 Genetic Polymorphisms on Warfarin Dosage

    Objective To investigate the influence of CYP2C9 3,VKORC1-1639 G>A and CYP4F2 rs2108622 genetic polymorphisms on warfarin dosages of patients after heart valve replacement. Methods A total of 133 patients undergoing heart valve replacement in the Department of Cardiovascular Surgery of Fujian Provincial Hospital from November 2011 to August 2012 were included in this study. Polymerase chain reaction(PCR)gene sequencing was performed to detect CYP2C9 3,VKORC1-1639 G>A and CYP4F2 rs2108622 genetic polymorphism of these 133 patients. Patients were grouped according to their genotypes,and average warfarin dosages were compared between different genotype groups. Results The frequencies of CYP2C9 3 AA,AC and CC were 127 patients,6 patients and 0 patient respectively,and average daily warfarin dosages were 3.75 mg and 2.13 mg respectively which were statistically different between differentCYP2C9 3 genotypes (P<0.05). The frequencies of VKORC1-1639 G>A GG,GA and AA were 3 patients,32 patientsand 98 patients respectively,and average daily warfarin dosages were 6.00 mg,4.50 mg and 3.00 mg respectively which were statistically different between different VKORC1-1639 G>A genotypes (P<0.05). The frequencies of CYP4F2 rs 2108622 CC,CT and TT were 67 patients,59 patients and 7 patients respectively,and average daily warfarin dosages were 3.00 mg,3.75 mg and 4.50 mg respectively which were statistically different between different CYP4F2 rs2108622 genotypes(P<0.05). Conclusion CYP2C9 3,VKORC1-1639 G>A and CYP4F2 rs2108622 genetic polymorphisms are associated with individual difference of warfarin dosages of patients after heart valve replacement.

    Release date:2016-08-30 05:47 Export PDF Favorites Scan
  • Comparison of three modes of blood flow blocking in hepatectomy for primary hepatocellular carcinoma

    ObjectiveTo compare the efficacy and safety of three different modes of blood flow blocking in hepatectomy for primary hepatocellular carcinoma.MethodsThe clinical data of 152 patients with primary hepatocellular carcinoma who underwent hepatectomy and postoperative pathology examination in our department in recent 3 years (2017–2020) were retrospectively analyzed. According to the modes of intraoperative hepatic blood flow occlusion, the patients were divided into three groups: intermittent Pringle method (IPM) group (41 cases), IPM was applied only; hemihepatic group (35 cases), hemihepatic blood flow blocking method was used only; and combined group (76 cases), combined hemihepatic blood flow blocking method and IPM. SPSS software was used to compare the differences of the three groups’ general data, intraoperative blood loss and postoperative liver function indexes. The changes of transaminase levels in the three groups were observed dynamically.ResultsBaseline data of the three groups were not statistically significant (P>0.05). There were no statistically significant differences in operative time, the number of resected liver segments, blood transfusion rate, incidence of complications, and postoperative length of stay among the three groups (all P>0.05). The intraoperative blood loss of the combined group and the IPM group were significantly less than that of the hemihepatic group (P<0.05). There was no difference in blood loss between the combined group and the IPM group (P>0.05). However, the blocking times in the combined group were significantly less than those in the IPM group (P<0.05). The transaminases in the three groups were close to the preoperative level on the fifth day after operation. Conclusions In hepatectomy of primary hepatocellular carcinoma, the three blocking modes are safe and effective. The combined application of hemihepatic blood flow blocking method and intermittent Pringle method can significantly reduce intraoperative blood loss, reduce the number of blocking, and do not aggravate the liver function injury.

    Release date:2021-06-24 04:18 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content